Betulinic Acid-Brosimine B Hybrid Compound Has a Synergistic Effect with Imatinib in Chronic Myeloid Leukemia Cell Line, Modulating Apoptosis and Autophagy

Betulinic Acid-Brosimine B Hybrid Compound Has a Synergistic Effect with Imatinib in Chronic Myeloid Leukemia Cell Line, Modulating Apoptosis and Autophagy

Chronic myeloid leukemia (CML) is a myeloproliferative disease characterized by the formation of the BCR-ABL (breakpoint cluster region-Abelson) oncoprotein. As many patients display therapeutic resistance, the development of new drugs based on semisynthetic products represents a new potential thera...

Full description

Bibliographic Details
Main Authors: Julia Biz Willig, Nádia Miléo Garcês de Couto, Débora Renz Barreto Vianna, Camila da Silveira Mariot, Simone Cristina Baggio Gnoatto, Andréia Buffon, Diogo André Pilger
Format: Article
Language:English
Published: MDPI AG 2023-04-01
Series:Pharmaceuticals
Subjects:
betulinic acid
brosimine B
imatinib
synergism
K-562
chronic myeloid leukemia
Online Access:https://www.mdpi.com/1424-8247/16/4/586

Internet

https://www.mdpi.com/1424-8247/16/4/586

Similar Items